Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTREPID: EDP-305 in Primary Biliary Cholangitis
NCT03394924Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Dec 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of EDP-305 in primary biliary cholangitis (PBC), sponsored by Enanta Pharmaceuticals. Started Dec 2017; status: completed.
02
Drugs
EDP-305
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03394924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03394924.